<?xml version='1.0' encoding='utf-8'?>
<document id="24694091"><sentence text="Dolutegravir for the treatment of adult patients with HIV-1 infection."><entity charOffset="0-12" id="DDI-PubMed.24694091.s1.e0" text="Dolutegravir" /></sentence><sentence text="Dolutegravir, is a second generation integrase inhibitor that had recently received United States Food and Drug Administration and European Commission approval for the treatment of adult patients with HIV-1 infection"><entity charOffset="0-12" id="DDI-PubMed.24694091.s2.e0" text="Dolutegravir" /></sentence><sentence text=" Dolutegravir provides distinct advantages compared with first generation integrase inhibitors"><entity charOffset="1-13" id="DDI-PubMed.24694091.s3.e0" text="Dolutegravir" /></sentence><sentence text=" Unlike raltegravir, dolutegravir can be given once daily for patients who are antiretroviral treatment naÃ¯ve"><entity charOffset="8-19" id="DDI-PubMed.24694091.s4.e0" text="raltegravir" /><entity charOffset="21-33" id="DDI-PubMed.24694091.s4.e1" text="dolutegravir" /><pair ddi="false" e1="DDI-PubMed.24694091.s4.e0" e2="DDI-PubMed.24694091.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24694091.s4.e0" e2="DDI-PubMed.24694091.s4.e1" /></sentence><sentence text=" Once-a-day dolutegravir dosing also does not require a pharmacokinetic booster like elvitegravir which minimizes the drug-drug interaction potential of dolutegravir"><entity charOffset="12-24" id="DDI-PubMed.24694091.s5.e0" text="dolutegravir" /><entity charOffset="85-97" id="DDI-PubMed.24694091.s5.e1" text="elvitegravir" /><entity charOffset="153-165" id="DDI-PubMed.24694091.s5.e2" text="dolutegravir" /><pair ddi="false" e1="DDI-PubMed.24694091.s5.e0" e2="DDI-PubMed.24694091.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24694091.s5.e0" e2="DDI-PubMed.24694091.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24694091.s5.e0" e2="DDI-PubMed.24694091.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24694091.s5.e1" e2="DDI-PubMed.24694091.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24694091.s5.e1" e2="DDI-PubMed.24694091.s5.e2" /></sentence><sentence text=" In Phase III clinical trials, dolutegravir-containing regimens have demonstrated either non-inferiority or superiority to current first line agents such as raltegravir, darunavir/ritonavir, and efavirenz containing regimens"><entity charOffset="31-43" id="DDI-PubMed.24694091.s6.e0" text="dolutegravir" /><entity charOffset="157-168" id="DDI-PubMed.24694091.s6.e1" text="raltegravir" /><entity charOffset="170-179" id="DDI-PubMed.24694091.s6.e2" text="darunavir" /><entity charOffset="180-189" id="DDI-PubMed.24694091.s6.e3" text="ritonavir" /><entity charOffset="195-204" id="DDI-PubMed.24694091.s6.e4" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e0" e2="DDI-PubMed.24694091.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e0" e2="DDI-PubMed.24694091.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e0" e2="DDI-PubMed.24694091.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e0" e2="DDI-PubMed.24694091.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e0" e2="DDI-PubMed.24694091.s6.e4" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e1" e2="DDI-PubMed.24694091.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e1" e2="DDI-PubMed.24694091.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e1" e2="DDI-PubMed.24694091.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e1" e2="DDI-PubMed.24694091.s6.e4" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e2" e2="DDI-PubMed.24694091.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e2" e2="DDI-PubMed.24694091.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e2" e2="DDI-PubMed.24694091.s6.e4" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e3" e2="DDI-PubMed.24694091.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24694091.s6.e3" e2="DDI-PubMed.24694091.s6.e4" /></sentence><sentence text=" Moreover, dolutegravir may be effective for patients with a history of raltegravir and/or elvitegravir resistance"><entity charOffset="11-23" id="DDI-PubMed.24694091.s7.e0" text="dolutegravir" /><entity charOffset="72-83" id="DDI-PubMed.24694091.s7.e1" text="raltegravir" /><entity charOffset="91-103" id="DDI-PubMed.24694091.s7.e2" text="elvitegravir" /><pair ddi="false" e1="DDI-PubMed.24694091.s7.e0" e2="DDI-PubMed.24694091.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24694091.s7.e0" e2="DDI-PubMed.24694091.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24694091.s7.e0" e2="DDI-PubMed.24694091.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24694091.s7.e1" e2="DDI-PubMed.24694091.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24694091.s7.e1" e2="DDI-PubMed.24694091.s7.e2" /></sentence><sentence text=" Dolutegravir will likely play a major role in the management of patients with HIV-1 infection, and will be aided when coformulation with abacavir/lamivudine as a single pill, once-daily regimen is available"><entity charOffset="1-13" id="DDI-PubMed.24694091.s8.e0" text="Dolutegravir" /><entity charOffset="138-146" id="DDI-PubMed.24694091.s8.e1" text="abacavir" /><entity charOffset="147-157" id="DDI-PubMed.24694091.s8.e2" text="lamivudine" /><pair ddi="false" e1="DDI-PubMed.24694091.s8.e0" e2="DDI-PubMed.24694091.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24694091.s8.e0" e2="DDI-PubMed.24694091.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24694091.s8.e0" e2="DDI-PubMed.24694091.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24694091.s8.e1" e2="DDI-PubMed.24694091.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24694091.s8.e1" e2="DDI-PubMed.24694091.s8.e2" /></sentence><sentence text=" " /></document>